ÀÌ¿¬¾Æ ¸íÀÇ

ÀÚ°¡¸é¿ªÁúȯ ȯÀÚÀÇ µçµçÇÑ µ¿¹ÝÀÚ

ÀÌ¿¬¾Æ ¸íÀÇ

  • ¼Ò ¼Ó
    °æÈñ´ëÇб³º´¿ø ·ù¸¶Æ¼½º³»°ú
  • Áø·á°ú
    ·ù¸¶Æ¼½º³»°ú
  • Àü¹®ºÐ¾ß
    ·çǪ½º, ·ù¸¶Æ¼½º°üÀý¿°, ôÃß°üÀý¿°, ¿°Áõ¼º ±ÙÀ°¿°, ÀÚ°¡¸é¿ªÁúȯ
·ù¸¶Æ¼½º Áúȯ Ä¡·áÀÇ Àü¹®°¡·Î ÀÎÁ¤¹Þ´Â ÀÌ¿¬¾Æ ±³¼ö´Â ÀÚ°¡¸é¿ªÁúȯ ºÐ¾ß¿¡¼­ ¶Ù¾î³­ ÀÓ»ó ¼º°ú¸¦ º¸À̰í ÀÖ´Ù. ȯÀÚ Áß½ÉÀÇ ¸ÂÃãÇü Ä¡·á¸¦ ÅëÇØ »îÀÇ Áú Çâ»ó¿¡ ÁÖ·ÂÇϰí ÀÖÀ¸¸ç, ÃֽŠ»ý¹°ÇÐÀû Á¦Á¦¸¦ Ȱ¿ëÇÑ Çõ½ÅÀû Ä¡·á¹ý °³¹ß¿¡ ±â¿©Çϰí ÀÖ´Ù. ·ù¸¶Æ¼½º Áúȯ¿¡ ´ëÇÑ ÀÎ½Ä °³¼±°ú Á¶±â Áø´ÜÀÇ Á߿伺À» °­Á¶Çϸç ÀÇ·á ¹ßÀüÀ» ¼±µµÇϰí ÀÖ´Ù.

¸íÀÇÇÁ·ÎÇÊ ¸íÀÇ ÇÁ·ÎÇÊ

ÇзÂ

  • °æÈñ´ë ÀÇ´ë Çлç
  • °æÈñ´ë ÀÇ´ë ¼®»ç
  • °æÈñ´ë ÀÇ´ë ¹Ú»ç

ÁÖ¿ä°æ·Â

  • úÞ) °æÈñ´ëÇб³º´¿ø ·ù¸¶Æ¼½º³»°ú ±³¼ö

¼ö»ó³»¿ª

  • International Scholarship- The 54th Annual General Assembly and Scientific Meeting of Japan College of Rheumatology

ÁýÇÊÀú¼­

ÃÑ 0°Ç

ÁÖ¿ä³í¹®

ÃÑ 7°Ç
Á¦ ¸ñ Frequency of peripheral diseases in Korean patients with ankylosing spondylitis and the effectiveness of adalimumab
¹ßÇ¥³âµµ 2020
¹ßÇ¥Áö
Á¦ ¸ñ Predicting Imaging Remission in Rheumatoid Arthritis: a Case-control Ultrasound Study
¹ßÇ¥³âµµ 2020
¹ßÇ¥Áö
Á¦ ¸ñ Seasonal Variations and Associated Factors of Gout Attacks: a Prospective Multicenter Study in Korea
¹ßÇ¥³âµµ 2020
¹ßÇ¥Áö
Á¦ ¸ñ Àü½ÅÈ«¹Ý·çǪ½ºÀÇ »õ·Î¿î ºÐ·ù ±âÁØ
¹ßÇ¥³âµµ 2020
¹ßÇ¥Áö
Á¦ ¸ñ Concurrent treatment with rituximab and plasma exchange for severe refractory granulomatosis with polyangiitis: A case report
¹ßÇ¥³âµµ 2019
¹ßÇ¥Áö
Á¦ ¸ñ A systemic lupus erythematosus patient with thunderclap headache: reversible cerebral vasoconstriction syndrome
¹ßÇ¥³âµµ 2019
¹ßÇ¥Áö
Á¦ ¸ñ Potential Therapeutic Antibodies Targeting Specific Adiponectin Isoforms in Rheumatoid Arthritis
¹ßÇ¥³âµµ 2018
¹ßÇ¥Áö

¸íÀÇqna ¸íÀÇ QnA

°¡Àå °ü½É ÀÖ´Â ºÐ¾ß¿Í ¾÷ÀûÀÌ ÀÖ´Ù¸é ¾Ë·ÁÁÖ¼¼¿ä
ȯÀÚ Áø·á¿¡ ÀÖ¾î °¡Àå Áß¿äÇÏ°Ô »ý°¢ÇÏ´Â °¡Ä¡´Â?
ȯÀڵ鿡°Ô ÀüÇÏ°í ½ÍÀº ¸»¾¸

¸íÀÇqna ¸íÀÇ ¼Ò¼Óº´¿ø

°æÈñ´ëÇб³º´¿ø

»ó±ÞÁ¾ÇÕº´¿ø
ÀüÈ­ ¾ÆÀÌÄÜ ´ëÇ¥¹øÈ£
02-958-8114
À¥»çÀÌÆ® ¾ÆÀÌÄÜȨÆäÀÌÁö
°æÈñ´ëÇб³º´¿ø À̹ÌÁö

ÁÖ¿ä½Ã¼³

ÀÀ±Þ½Ç ÀÀ±Þ½Ç
Ŭ¸®´Ð Ŭ¸®´Ð
Á¾ÇÕ°ËÁø¼¾ÅÍ Á¾ÇÕ°ËÁø¼¾ÅÍ
¾Ï¼¾ÅÍ ¾Ï¼¾ÅÍ
ÁÖÂ÷½Ã¼³ ÁÖÂ÷½Ã¼³

°æÈñ´ëÇб³º´¿øÀº ȯÀÚ Áß½ÉÀÇ ÀÇ·á ¼­ºñ½º¸¦ Á¦°øÇϸç, ±¹³» ÀÇ·á°è¸¦ ¼±µµÇÏ´Â »ó±ÞÁ¾ÇÕº´¿øÀÔ´Ï´Ù. ÃֽŠÀÇ·á ±â¼ú°ú Àåºñ¸¦ Ȱ¿ëÇÏ¿© ȯÀڵ鿡°Ô ÃÖ»óÀÇ Ä¡·á¸¦ Á¦°øÇÕ´Ï´Ù. ƯÈ÷ ÁßÁõÁúȯ Ä¡·á ¹× ¿¬±¸¿¡ °­Á¡À» º¸À̸ç, ´ÙÇÐÁ¦ ÇùÁø ½Ã½ºÅÛÀ» ÅëÇØ ȯÀÚÀÇ °Ç°­À» ÃÖ¿ì¼±À¸·Î »ý°¢ÇÕ´Ï´Ù. °æÈñ´ëÇб³º´¿øÀº ȯÀÚµéÀÇ ½Å·Ú¿Í ¸¸Á·µµ¸¦ ³ôÀÌ´Â µ¥ ÁÖ·ÂÇϸç, Áö¼ÓÀûÀ¸·Î ÀÇ·á ǰÁú Çâ»ó°ú ¿¬±¸ °³¹ß¿¡ Èû¾²°í ÀÖ½À´Ï´Ù.

¼­¿ïƯº°½Ã µ¿´ë¹®±¸ °æÈñ´ë·Î 23 °æÈñ´ëÇб³º´¿ø

Ȩ
³»°¡ ¾Ë°íÀÖ´Â ¸íÀǸ¦ ÃßÃµÇØÁÖ¼¼¿ä